title: N-Acetylcysteine prevents baker's-yeast-induced inflammation and fever.
abstract: OBJECTIVE
  To investigate whether N-acetylcysteine (NAC) alters baker's-yeast-induced fever and inflammation.
  
  
  METHODS
  Male Wistar rats (26-28 days old) injected with baker's yeast (135 mg/kg, intraperitoneal) or prostaglandin E(2) (300 ng/100 μL, intrathecal).
  
  
  METHODS
  Rats were injected with NAC (500 mg/kg, subcutaneous, or 50 μg/100 μL, intrathecal) 1 h before, or 2 h after, pyrogen injection.
  
  
  METHODS
  Rectal temperature changes induced by baker's yeast, PGE(2) and NAC were followed up over time. Four hours after baker's yeast injection, total leukocytes, protein, interleukin (IL)-1β, tumor necrosis factor (TNF)-α and nonprotein thiol content were assessed in peritoneal lavage and hypothalamus.
  
  
  RESULTS
  Systemic administration of NAC decreased leukocytes, protein, IL-1β and TNF-α levels in peritoneal lavage, and decreased IL-1β levels in the hypothalamus. The central administration of NAC prevented baker's-yeast-induced fever, but did not alter the febrile response elicited by prostaglandin E(2).
  
  
  CONCLUSIONS
  These results suggest an anti-inflammatory and antipyretic role for NAC in yeast-induced peritonitis.
authors: Department of Physiology and Pharmacology, Center of Health Sciences, Universidade Federal de Santa Maria (UFSM), Santa Maria, RS, 97105-900, Brazil.
authors: Ana Paula Oliveira
authors: AP
authors: Ferreira
authors: Juliana Saibt Martins
authors: JS
authors: Pasin
authors: André Luis Lopes
authors: AL
authors: Saraiva
authors: Viviane
authors: V
authors: Ratzlaff
authors: Mateus Fortes
authors: MF
authors: Rossato
authors: Rosália
authors: R
authors: Andrighetto
authors: Maribel Antonello
authors: MA
authors: Rubin
authors: Juliano
authors: J
authors: Ferreira
authors: Carlos Fernando
authors: CF
authors: Mello
mesh_terms: D000111:Acetylcysteine / Q000494:pharmacology / Q000627:therapeutic use*; D000818:Animals; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000494:pharmacology / Q000627:therapeutic use*; D058633:Antipyretics / Q000494:pharmacology / Q000627:therapeutic use*; D015232:Dinoprostone / Q000494:pharmacology; D005334:Fever / Q000188:drug therapy* / Q000382:microbiology; D016166:Free Radical Scavengers / Q000494:pharmacology*; D007031:Hypothalamus / Q000737:chemistry / Q000378:metabolism; D053583:Interleukin-1beta / Q000032:analysis; D007958:Leukocyte Count; D008297:Male; D010533:Peritoneal Lavage; D010538:Peritonitis / Q000188:drug therapy* / Q000378:metabolism / Q000382:microbiology; D011506:Proteins / Q000032:analysis; D051381:Rats; D017208:Rats, Wistar; D012441:Saccharomyces cerevisiae / Q000187:drug effects*; D014409:Tumor Necrosis Factor-alpha / Q000032:analysis
chemical_list: D000894:Anti-Inflammatory Agents, Non-Steroidal; D058633:Antipyretics; D016166:Free Radical Scavengers; D053583:Interleukin-1beta; D011506:Proteins; D014409:Tumor Necrosis Factor-alpha; D015232:Dinoprostone; D000111:Acetylcysteine